Utilizing advanced imaging to explore early effects of SGLT2 inhibition on myocardial function and metabolism in type 2 diabetes
April 26th, 2021
A recent study, sponsored by AstraZeneca, exploring the early effects of sodium-glucose co-transporter-2 inhibition (SGLT2i) on myocardial function and metabolism in patients with type 2 diabetes has been published online in Diabetes, Obesity and Metabolism, with contribution from Antaros Medical. Imaging with magnetic resonance imaging (MRI) and positron emission tomography (PET) was central in the study to provide insights on potential mechanisms behind cardiovascular (CV) benefits of SGLT2 inhibition in type 2 diabetes.
“This study provides an example of how advanced imaging can be used to give additional understanding of drug mechanisms” Olof Eriksson, PET Imaging Director, Antaros Medical
SGLT2 inhibition is approved for treatment of type 2 diabetes. CV complications such as heart failure are common in this patient population and it has been shown that SGLT2 inhibition is also linked to CV benefits both in patients with and without type 2 diabetes. Several mechanisms have been proposed and are being investigated. The published study adds to the current understanding of the positive effects of SGLT2 inhibition in type 2 diabetes.
The design of the study has been published previously with Lars Johansson (Chief Scientific Officer at Antaros Medical) as one of the co-authors.
Read the publications here:
Title: Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study
Authors: Oldgren J, Laurila S, Åkerblom A, Latva-Rasku A Rebelos E, Isackson H, Saarenhovi H, Eriksson O, Heurling K, Johansson E, Wilderäng U, Karlsson C, Esterline R, Ferrannini E, Oscarsson J, Nuutila P
Authors: Åkerblom A, Oldgren J, Latva-Rasku A, Johansson L, Lisovskaja V, Karlsson C, Oscarsson J, Nuutila P
Back to all news